Odyssey Therapeutics Inc. (ODTX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

ODTX scores 52 out of 100, a letter grade of D+ with the verdict label "Roarable Sell — Weak Fundamentals / Trim." The five pillars are:

• Fundamental cash engine: 10 / 20. The rating reflects ROIC of 0% and FCF yield of 0%. For a prospective investor, this means the source data shows no measurable return on invested capital and no free-cash generation to support the valuation from operations.
• Whale 13F flow: 7 / 20. This pillar reflects institutional accumulation and options positioning.
• Insider conviction: 9 / 20. This pillar reflects SEC Form 4 and Congressional PTR cluster flow. No insider transaction records are present in the holders section, so the score cannot be traced to specific trades here.
• Macro regime fit: 13 / 20. Per the rating, beta is 1.0 and the score reflects sector sensitivity, meaning the stock is rated as moving in line with the broader market rather than offering a defensive or differentiated beta profile.
• Forensic balance sheet: 13 / 20. Per the rating, Altman Z is 2.5, Piotroski F is 6/9, and Debt/Equity is 0.5. This is the strongest pillar and suggests a moderately sound balance sheet relative to the weak cash-generation picture.

Taken together, the rating points to a valuation supported more by balance-sheet resilience and market narrative than by current cash earnings. The upside driver a prospective investor would weigh is the balance-sheet pillar and the news flow; the valuation tradeoff is that the 10/20 cash-engine score leaves no earnings base to anchor price targets. The rating's verdict is a trim signal, not a recommendation to act.

And profile, Odyssey Therapeutics Inc. (ODTX) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. The profile reports a market capitalization of $1.0B. Per the news wire, the company's disclosed development activity centers on OD-001 in ulcerative colitis, with Phase 2a data and presentations referenced.

FY 2025 reports zero revenue, zero operating income, and zero net income, with cash of $41.7M. Gross, operating, and net margins are each 0% per the market data, and ROIC is 0%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 6/9, with Debt/Equity of 0.5.

• 🐂 Primary Bull Case: The balance sheet scores 13/20 on Altman Z 2.5, Piotroski F 6/9 and Debt/Equity 0.5, and the news wire flags continued positive OD-001 Phase 2a ulcerative colitis data. With Fundamental Cash Engine at 10/20 (ROIC —, FCF yield —) and Institutional Whale Flow at 6/20, sustained execution supports upside toward the top of the $15.10 – $29.05 52-week range.
• 🐻 Primary Bear Case: Revenue, operating income, net income, ROIC and FCF yield are all reported at zero, leaving the cash-engine pillar at 10/20. Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.

Supply chain is "NONE" and butterfly links are empty, so upstream and downstream dependencies cannot be mapped from source data. Sector correlation is limited to the Health Care / Biological Products classification and beta of 1.0. Second-order bottlenecks to watch are not identifiable from the provided sources; clinical-readout timing tied to the OD-001 program is the principal catalyst thread in the news wire.

• Key Question #1: What is the company's cash burn rate and runway given $41.7M in cash and zero revenue?
• Key Question #2: What is the debt balance in dollar terms, given Debt/Equity of 0.5 but debt reported as N/A?
• Key Question #3: What are the milestone timelines and clinical-readout dates for OD-001?